Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Digital Therapeutics Landscape in Europe

    September 3, 2020 |  

    OPEN Health introduce an overview of regulatory and HTA developments for digital therapeutics in Europe focusing on Germany and the UK

    Digital Therapeutics Landscape in Europe: The Case of Germany and the UK

    The COVID-19 virus crisis has opened immense windows of opportunity in healthcare around the globe. One of the greatest opportunities is in digital health, and in particular, digital therapeutics (DTx). The need for continued medical care combined with social distancing has led to a spike in use of digital health tools worldwide.1 As the interest in and use of digital health has grown during this period, we anticipate that investments in digital health tools will continue to accelerate after the COVID-19 pandemic. When the COVID-19 outbreak started, millions of Chinese people turned to online doctors and online health tools1 to find the needed support for their health. While these developments could create new risks for privacy and data protection, they also represent an unprecedented opportunity to integrate industry 4.0 in healthcare for the benefit of patients.

    HIGHLIGHTS INCLUDE:
    • Opportunities and threats of digital therapeutics after COVID-19
    • Digital therapeutics landscape in the European Union
    • Review and comparison of the German and UK therapeutics landscape
    • Develop game-changing insights and competitive advantage on both a global and local scalepi

    Pink divider

    Download the white paper and learn how it’s happening now!

    Download the Paper- PMLiVE

    1. https://www.cnbc.com/2020/03/26/investments-in-digital-health-care-could-accelerate-after-coronavirus-credit-suisse-says.html

    This content was provided by OPEN Health

    Company Details

    OPEN Health

    OPEN Health

    Email
    Website

     Latest Content from  OPEN Health 

    OPEN Health’s response to the FDA’s guidance on long term follow up post gene therapy

    Written by Gavin Jones, OPEN Health

    OPEN Health expands offering with the launch of a new Learning & Development specialist team

    Enhanced expertise to deliver impactful internal training programmes for healthcare clients

    Spotlight interview: 15 minutes on healthcare communications in gene therapy

    Gavin Jones, Director of Rare Disease, OPEN Health takes 15 minutes to answer some key questions on healthcare communications in gene therapy

    OPEN Health becomes sponsor of MedComms Networking

    New for 2020, OPEN Health is pleased to announce its sponsorship of MedComms Networking

    OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications

    Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications

    Spotlight interview: 15 minutes on digital in medical communications

    Gemma Allen, Head of Digital Communications, OPEN Health takes 15 minutes to answer some key questions on digital in medical communications

    Generating data on long-term outcomes with gene and other advanced therapies

    Gene therapy and advanced cell-based therapies offer patients hope and the potential to make them ‘chronically well’.

    Are you using Patient-Reported Outcomes (PROs) in your oncology trials? If not, why not?

    A recent blog, published by Sarah Tressel Gary and Rinah Yamamoto called “Patient-Reported Outcome Data in Oncology Trials - Part 2: Clinical Benefit and Patient Preference”, has sparked our interest....

    Spotlight interview: 15 minutes on insights and market research in pharma

    Neil Rees, Head of Research, OPEN Health Patient & Brand Communication takes 15 minutes to answer some key questions on insights and market research in pharma

    OPEN Health reflections on the World Orphan Drug Congress in Barcelona

    Having just returned from a very busy but hugely enjoyable few days at congress, I wanted to share our views on the event and key themes that our healthcare communications...